Phase II SBIR grant supports ONL Therapeutics' development of ONL-101 in retinal detachment Nov. 13, 2014 No Comments
RetroSense Therapeutics gene therapy gains FDA orphan drug status for retinitis pigmentosa Oct. 27, 2014 No Comments
Phase I/II results for cell therapy-based replacement of retinal pigment epithelium Oct. 23, 2014 No Comments
RSS